RayKnowChina Research Map
Shortlist

Not yet recruitingLung cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

A Phase 2 Study of ABSK043 Combined With Osimertinib

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 7 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. NSNLC confirmed by tissue or cytological pathology. NSCLC with a mixed histology is eligible, if adenocarcinoma is the predominant histology.

    Inclusion criterion 3

  3. Participants must have received ≥2 prior lines of frontline systemic therapy.

    Inclusion criterion 7

    Has a history of interstitial lung disease (ILD)/pneumonitis or active ILD 3. Spinal cord compression and unstable brain metastases. 4.Any unresolved toxicities from prior systemic therapy greater than CTCAE v6.0 Grade 1 at the time of starting study treatment.

    Exclusion criterion 2

  4. ECOG score 0-1 at screening.

    Inclusion criterion 14

  5. 1. Histological or cytological examinations suggest that NSCLC squamous cells is the predominant histology, or contains small cell lung cancer, neuroendocrine carcinoma, etc.

    Exclusion criterion 1

    Participants with known HIV infection.

    Exclusion criterion 5

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07710612, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Aged 18 or above, male or female.
  • Participants must understand and voluntarily participate in this study and must have been provided informed consent for study participation.
  • NSNLC confirmed by tissue or cytological pathology. NSCLC with a mixed histology is eligible, if adenocarcinoma is the predominant histology.
  • Diagnosed locally advanced or metastatic NSCLC
  • Different requirements for specific cohort:

Dose escalation and backfill cohorts:

  • Participants with disease in the adjuvant setting, post chemoradiotherapy setting, locally advanced stage or metastatic stage, who have received at least one prior line of third-generation EGFR-TKI-based monotherapy or combination therapy and experienced disease progression.
  • Participants must have received ≥2 prior lines of frontline systemic therapy.
  • Documented or central laboratory test report confirms that the tumor is PD-L1 expression positive (TPS/TC≥1%).
  • Documented genetic testing report confirms the presence of EGFR alteration(s) in tumor or plasma.

Expansion cohort(s):

  • Participants must not have received any other prior systemic cancer therapies in the locally advanced/metastatic setting for locally advanced or metastatic disease.
  • Central laboratory test report confirms that the tumor is PD-L1 expression positive (TPS/TC≥1%).
  • Documented genetic testing reports confirm the presence of EGFR
  • Presence of at least one measurable tumor lesion
  • ECOG score 0-1 at screening.
  • The expected life expectancy after the first dose is >12 weeks.

Exclusion Criteria:

  • 1. Histological or cytological examinations suggest that NSCLC squamous cells is the predominant histology, or contains small cell lung cancer, neuroendocrine carcinoma, etc.
  • Has a history of interstitial lung disease (ILD)/pneumonitis or active ILD 3. Spinal cord compression and unstable brain metastases. 4.Any unresolved toxicities from prior systemic therapy greater than CTCAE v6.0 Grade 1 at the time of starting study treatment.
  • Participants with obvious and unstable pleural effusion, peritoneal effusion or pericardial effusion .
  • Has a history of other malignant tumors, or currently have other malignant tumors.
  • Participants with known HIV infection.

Quoted from ClinicalTrials.gov, NCT07710612, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07710612, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07710612